The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.
Keywords: Anakinra; Azithromycin; COVID-19; Chloroquine; Convalescent plasma; Epoprostenol; Favipiravir; Hydroxychloroquine; Lopinavir; Methylprednisolone; Nitric oxide; Oseltamivir; Remdesivir; SAR-CoV-2; Sarilumab; Sirolimus; Tocilizumab; Traditional Chinese Medicine; Umifenovir; Vitamin C.
© Springer Nature Switzerland AG 2020.
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.Curr Med Chem. 2020 Apr 16. doi: 10.2174/0929867327666200416131117. Online ahead of print. Curr Med Chem. 2020. PMID: 32297571
Potential therapeutic agents against COVID-19: What we know so far.J Chin Med Assoc. 2020 Apr 1:10.1097/JCMA.0000000000000318. doi: 10.1097/JCMA.0000000000000318. Online ahead of print. J Chin Med Assoc. 2020. PMID: 32243270 Free PMC article.
Potential specific therapies in COVID-19.Version 2. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926853. doi: 10.1177/1753466620926853. Ther Adv Respir Dis. 2020. PMID: 32436445 Free PMC article. Review.
Pharmacotherapy in COVID-19; A narrative review for emergency providers.Am J Emerg Med. 2020 Apr 15:S0735-6757(20)30263-1. doi: 10.1016/j.ajem.2020.04.035. Online ahead of print. Am J Emerg Med. 2020. PMID: 32336586 Free PMC article. Review.
The Rationale for Potential Pharmacotherapy of COVID-19.Pharmaceuticals (Basel). 2020 May 14;13(5):E96. doi: 10.3390/ph13050096. Pharmaceuticals (Basel). 2020. PMID: 32423024 Review.